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Abstract Over the past few decades, significant scientific
progress has influenced clinical allergy practice. The biolog-
ical standardization of extracts was followed by the massive
identification and characterization of new allergens and their
progressive use as diagnostic tools including allergen micro
arrays that facilitate the simultaneous testing of more than 100
allergen components. Specific diagnosis is the basis of allergy
practice and is always aiming to select the best therapeutic or
avoidance intervention. As a consequence, redundant or irrel-
evant information might be adding unnecessary cost and
complexity to daily clinical practice. A rational use of the
different diagnostic alternatives would allow a significant
improvement in the diagnosis and treatment of allergic pa-
tients, especially for those residing in complex pollen expo-
sure areas.
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Introduction
In contrast to tropical areas, where mites are the leading and
almost sole cause of respiratory allergy, in temperate regions,
such as Europe or North America, pollen plays a major role in
allergic patient sensitization.
There are important differences in pollen sensitization
profiles. Grasses, mainly from the Poaceae family, are
the most frequent pollen sensitizers. In north and central
Europe, birch pollinosis ranks second in allergy trigger-
ing and together with grasses account for most of the
pollen-related allergic symptoms [1].
Mediterranean and dry areas present quite different
pollen exposure patterns. In addition to grasses, other
pollens, such as Oleaceae, Amaranthaceae, Cupressaceae,
Asteraceae, and Urticaceae, play a significant clinical role
[2, 3]. In North America, there are pollen regions coinci-
dent with European ones with the added complexity of
greater tree diversity and a high incidence of ragweed
pollinosis [4, 5]. Ragweed pollinosis was exported at the
beginning of the twentieth century to central Europe and
has steadily increased since then [6, 7]. Other pollinosies
caused by plants originating in desert regions are also of
increasing importance in semi desertic areas.
Pollen extracts used for diagnosis consist of the complex
mixtures of major allergens (sensitizing more than 50% of the
patients allergic to a particular pollen), minor allergens, with a
lower prevalence, pan-allergens, and non-allergenic mole-
cules [8•]. Major allergens are relatively abundant molecules
that are good markers of primary sensitization in general.
Minor allergen may be of importance for identifying differen-
tial, oftenmore severe, clinical phenotypes and rarely sensitize
patients independently from major allergens [9].
Pan-allergens are highly conserved molecules present in
practically all pollens (and, in some cases, in vegetable foods)
and are highly cross-reactive [10–12]. As a consequence,
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patients sensitized to pan-allergens will yield positive extract-
based diagnosis to multiple pollens and foods.
Biological standardization consist of assigning a potency to
an extract that is related to the biological activity in a dose-
response skin test procedure performed on a representative
sample of allergic patients [13–16].While frequent sensitizers,
such as grasses or birch, can be easily standardized, pollens
with low prevalence in the allergic population are difficult to
standardize and can be biased, at least partly, to pan-allergen-
sensitized populations [2]. It can be estimated that at least
20 % of pollen-allergic patients are sensitized to pan-allergens
and will yield positive skin responses to almost any pollen
extract. These extracts will be highly unspecific, and they add
further noise to an already-complex diagnostic situation.
The combination of complex pollen exposure to many
pollens, pan-allergen prevalence, and poorly standardized ex-
tracts often makes the correct diagnosis of allergic patients
resident in these areas by extract-based diagnosis almost im-
possible [17]. Thus, there is a misperception of extreme poly-
sensitization and an urgent need to simplify and improve
diagnosis in daily clinical practice.
The increasing availability of new in vitro diagnostics
incorporating single-allergenic molecules either as single-
allergen components, multiplexed, or in microarrays has im-
pacted clinical practice in allergy diagnosis allowing a more
accurate identification of leading sensitizers [18, 19••, 20–25].
However, there are still some problems that must be over-
come. The high price of most of the available methods makes
it desirable to define a rational use, as many health care
providers cannot finance their indiscriminate use. Incomplete,
redundant, or inadequate molecular panels, non-automated
procedures, non-validated allergens, and poor-quality mole-
cules make mass application of these protocols difficult and
reduce their efficacy since an expert scientific background is
required tomake a reliable diagnosis.Wewill review available
information in order to identify pragmatic diagnosis ap-
proaches using a combination of existing procedures and
technologies to improve current practices for specific allergy
diagnosis with a focus on patients living in complex pollen
regions.
Skin Prick Testing Diagnosis
Skin prick testing constitutes the primary allergy diagnostic
tool, providing quick and relevant results, being also relatively
inexpensive. Introducing single-allergen components in skin
prick test, daily clinical practice would constitute a significant
improvement. However, regulatory burdens make a massive
molecule-based skin prick test (SPT) commercialization al-
most impossible, at least in the near future. However, it would
be feasible to introduce a limited number of new approaches
that might allow the identification of pan-allergen reactors [2,
26, 27]. By doing this, the subset of patients that cannot be
diagnosed by SPT might be quickly identified, allowing a
better diagnosis in the remaining patients. Profilin and lipid-
transfer protein (LTP) SPT diagnostics are already available in
some European countries. Profilin is the most frequent pan-
allergen sensitizer, and it is normally linked to grass pollinosis
[3, 28•] with a prevalence increasing along grass pollen gra-
dients, that is, with increased grass pollen counts that includes
both pollen peaks and pollinization period and is associated
with a characteristic food allergic phenotype that might also be
a good indicator of grass pollen allergy severity. In some
areas, profilin prevalence reaches 60 % of pollen-allergic
patients. In regions with a lower profilin prevalence but with
multiple pollen allergies, testing with profilin might allow the
identification of 10–15 % of patients that cannot be diagnosed
by SPT and would consequently enable a quick diagnosis of
most patients by extract-based skin prick test.
If pan-allergen diagnostics are not available, a good alter-
native would be to use an extract made from a pollen that is
irrelevant for the resident population, such as a palm tree
pollen extract [27]. Positive response to such an extract would
mark unspecific responses to multiple pollens, so alternative
diagnostic procedures might be advisable. Negative palm tree
pollen response indicates a reliable SPT procedure to the
remaining pollens. Unspecific SPT responses might be due
to pan-allergens, residual pollen cross-contamination, or even
to cross-reactive carbohydrate determinant (CCD) reactivity
in some cases.
Apart from controls for unspecific reactions, the selected
panel of pollen extracts should be designed according to the
pollens in the area avoiding the use of redundant cross-
reactive extracts [29].
Major Allergen Markers and Cross-Reactivity
Major allergen sIgE-based diagnosis is an extremely valuable
diagnostic tool. First, major allergens sensitize most allergic
patients to a particular pollen; second, and more importantly,
diagnoses and specific therapies are standardized and adjusted
in relation to the major allergens [30–35]. As a consequence in
most cases, major allergen-based diagnosis will be enough to
correctly diagnose and, thus, adequately select extracts to treat
more than 90 % of allergic patients. Patients that are not
sensitized to major allergens or pan-allergens do exist but
normally represent less than 10 % of the allergic population,
and there is little evidence of the effect of major allergen-
adjusted therapies in this type of patients.
The following is a brief summary of both major and clin-
ically relevant minor pollen allergens and their cross-reactivity
that can be used for the diagnosis of patients resident in
complex pollen areas
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Grasses
Grass allergy to the Pooideae subfamily can basically be
diagnosed with two major allergens Phl p 1 and Phl p 5
[36–40]. All major allergens belonging to this subfamily
present a very high similarity degree [41, 42], and there is
scientific evidence that a single species or even single major
allergen isoform can be successfully used for patient treatment
[43–46].
About 10% of grass-allergic patients can be negative to Phl
p 1 and 5 and sensitized to other grass allergens such as Phl p
2, Phl p 4, or Phl p 11.
Prevalence of Phl p 1 is very high (close to 90%), while Phl
p 5 prevalence, depending on the areas, ranks from 50 to 80%.
Pan-allergen profilin behaves as a minor grass allergen, and its
prevalence is associated with Phl p 5 [3]. Recently, severe
profilin-mediated food allergy reactions have been described
[28•]. Interestingly, sIgG4/sIgE levels to Phl 5 and Phl p 2
were lower in patients suffering severe reactions. Profilin
sensitization and food allergy symptoms induced by profilin
correlates with grass allergy severity [28•]. It is important to
mention that profilin sIgE readouts should be made globally
without taking into account sIgE values to the different
profilins to assign profilin sensitization procedence. In some
diagnostic systems, such as ISAC-CAP, several profilins are
included with very different performance. For instance, rPhl p
12 normally shows a much lower sensitivity, probably in
relation to inadequate isoform election or incorrect folding.
Other allergenic grasses belonging to Panicoideae (John-
son grass and Bahia grass) or Chloridoideae (Bermuda grass)
lack group 5 allergens but do have group 1 allergen that
displays a high (around 70 %) sequence identity with Phl p
1. In extensive epidemiological studies testing both Cyn d 1
and Phl p 1, very few patients positive to Cyn d 1 and negative
to Phl p 1 were found [47]. To date, there is no clinical
evidence for the incremental effect of adding any of the non-
Pooideae subfamily species in immunotherapy formulas in
grass-allergic patients. Biological standardization procedures
performed on these latter species will overdose group 1 aller-
gens compared to Pooideae, where group 5 allergen greatly
contributes to biological potency. Basically, for species lack-
ing group 5, the extracts will be tested in the same grass-
allergic population, but the concentration of group 1 allergens
will be increased to compensate for group 5 absence as the
target of biological standardization is to induce a defined
quantitative biological response (wheal area). Consequently,
up to 40 % of grass-allergic patients that are group 1
monosensitized might react stronger to Bermuda, Bahia, or
Johnson grass extracts, without any clinically relevant impli-
cation. In commercial platforms, rPhl p 1 is included together
with nCyn d 1; thus, strong CCD reactors might yield positive
reactivity to nCyn d 1 and negative to rPhl p 1, the former
being unspecific. Moreover, we will be comparing a single
isoform with the multiple isoforms included in a natural
allergen preparation. To date, there is no major allergen mark-
er commercially available for Johnson and Bahia grass (Sor h
1 and Pas n 1).
Polcalcins, a group of pan-allergens that includes Phl p 7,
sensitize between 5 and 10 % of pollen-allergic patients and
are not associated with any particular pollen. It is a diagnostic
confounding factor and, when found as a sensitizer together
with profilin, is linked to more complex sensitization profiles
and many years of disease evolution [2]. As a consequence, it
should be incorporated into diagnostic panels for CRD.
Birch/Oak Pollen Allergy
Bet v 1 is the best marker of PR10 related tree pollen allergy.
In the US, where there is an important contribution of oak tree
pollen to tree pollen-allergic phenotypes, it might be interest-
ing to test the homologous allergen Que a 1 as well, which is
not currently commercially available in component-resolved
diagnostic (CRD) platforms.
Several PR10 molecules are incorporated in some arrays
used for CRD, both pollen and food related. Therefore, a
global interpretation should be performed evaluating food
allergy in the context of PR10 allergy. Practically all patients
with strong Bet v 1 recognition will yield a positive response
to most PR10 allergens due to cross-reactivity to Bet v 1 (or
Que a 1)
Oleaceae
Major olive pollen allergen Ole e 1 can be used as a marker of
sensitization. Ole e 1 is fully cross-reactive to ash tree major
allergen Fra e 1, so olive extract can be used to diagnose and
treat ash tree pollen-related allergy, which is relatively preva-
lent in some areas of central Europe [48, 49]. The same
similarity degree is also shown by the other six sequences
recently analyzed in ash pollen corresponding to the counter-
part in olive pollen [50]. The broad family of Ole e 1-like
proteins contains members in many if not all types of pollens,
but neither their relations nor their allergenic relevance are as
close as those between Ole e 1 and Fra e 1.
Patients living in areas overexposed to olive tree pollen
become sensitized to minor allergens, displaying a different
and more severe phenotype. The inclusion of minor allergens
such as Ole e 7 (belonging to non-specific lipid-transfer pro-
tein (nsLTP) family) and Ole e 9, olive pollen β-glucanase, is
necessary to identify these patients [51]. In fact, in these
extremely exposed areas, there are a significant proportion
of patients negative to Ole e 1 and positive to Ole e 7. These
could even present negative skin prick test responses to olive
pollen because of the low concentration of this minor allergen
in the whole pollen extracts [52].
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Cupressaceae
Cup a 1, Cup s 1, and Jun a 1 are major allergens of different
cypress species with a very extensive cross-reactivity [53]. As
a consequence, any of them can be used to identify cypress
sensitization. In Japan, where Japanese cedar allergy is very
prevalent [54], Cry j 1 should also be added. To date, there is
no efficient procedure to clone and express cypress allergens,
and as a consequence, natural forms are incorporated in CRD
procedures with the corresponding lack of specificity due to
CCD cross-reactivity [55, 56]. In the interpretation of these
results, other glycosylated molecules such as nJug r 2, nPhl p
4, or the MUXF3 CCD marker should be taken into account.
Amaranthaceae (Salsola and Chenopodium)
The relevance of these allergies, typical from desert regions, is
increasing in countries as Spain because of their resistance to
saline soils and dryness. Sal k 1 is a marker of Salsola allergy
(Russian thistle) [57] that is the leading sensitizer of this
pollen family. The inclusion of an allergen such as Che a 1
[58], cross-reactive between the different Salsola and
Chenopodium species, contributes to the diagnosis of
Amaranthaceae allergic patients.
Asteraceae (Artemisia, Ambrosia)
Asteraceae pollen, particularly ragweed, is a main cause of
clinical allergy over extensive North American regions. Art v
1 for Artemisia species and Amb a 1 for Ambrosia (ragweed)
allow a correct identification of most of Asteraceae-sensitized
patients [59, 60]. Art v 3 is a lipid-transfer protein ofArtemisia
pollen partly cross-reactive with Pru p 3, the main LTP syn-
drome marker. Sensitization to Art v 3 in the absence of Art v
1 should be interpreted in the context of LTP allergy.
Urticaceae (Parietaria)
Par j 2 is the main marker of Parietaria sensitization [61],
highly prevalent in Mediterranean countries. In spite of being
an nsLTP, as also occurs with the olive pollen nsLTP, Ole e 7,
Par j 2 is not cross-reactive to any other known allergen [62].
Plantaginaceae (Plantago)
Plantain allergy is difficult to assess as the pollen season
overlaps with that of grasses. There is a specific marker, Pla
l 1 [63], an Ole e 1-like member, that is available for specific
diagnosis. Epidemiological studies suggest that plantain aller-
gy is relevant in some areas [2, 3].
Platanaceae (Platanus)
Pla a 1 and Pla a 2 [64, 65] identify Platanus sensitization. In
areas with very high exposure to this pollen, as Barcelona
[66], Pla a 3, the LTP from the pollen [67], sensitizes some
patients. As this protein has partial cross-reactivity with food
LTPs, its sensitization should be evaluated in the context of
LTP allergy as to Art v 3.
Non-specific Lipid-Transfer Proteins (nsLTPs)
LTP-mediated allergy is a complex food-pollen syndrome
with a particularly high incidence in Mediterranean countries.
Given the currently active research on LTPs, a better under-
standing of the real worldwide incidence of LTP allergy will
be available in the coming years. As an example, Artemisia-
related LTP sensitization has recently been described in north-
ern China [68], suggesting that LTP allergy is relevant in other
regions apart from theMediterranean border. Peach LTP, Pru p
3, [69] is, in most cases, the leading LTP allergen.While some
patients are only reactive to a limited number of LTPs (mainly
from Rosaceae), some others develop sensitization and side
reactions to multiple LTPs, in what is known as the LTP
syndrome [70, 71]. Exposure to cross-reactive pollen contain-
ing LTPs seems to correlate with a higher recognition LTP
pattern. Currently, a panel of different LTPs from foods and
pollens is available for diagnosis, but the interpretation of
these results is often complex.
Sensitization and Clinical Relevance
SPT-based epidemiological surveys together with aerobiolog-
ical pollen data [1, 7, 68, 72–75] in correlation with allergic
symptoms have been the basis for defining clinically relevant
sensitizations. Apart from the previously described problems
associated with extract-based diagnosis, it is not always pos-
sible to define the relevant allergens for a particular population
and even more difficult to make a choice of the clinically
relevant sensitizers for a particular patient. Coincident pollen
seasons, long and discontinuous pollinization, pollens with
low aerovagant capacity but able to sensitize by close contact
or in areas with sustained strong winds and different sensiti-
zation threshold for different populations can at least partly
explain the complexity of the problem.
CRD offers a new tool to understand the complex dynam-
ics underlying patient sensitization. In a systemic epidemio-
logical study performed throughout Spanish territory, more
than 2000 patients homogenously distributed over the territory
were sampled from the allergic population [2, 3]. The results
obtained allowed the main sensitizers to be identified in the
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different regions, according to prevalence to major and minor
allergens.
An alternative way of analyzing the data consists in classi-
fying resident patients according to their sensitization profiles.
By clustering patients in such a way and considering only the
first three sensitization frequencies, we constructed Table 1.
This table also shows the prevalence to profilin and the
coverage of the first three frequencies by region.
When analyzing the data, three clinically relevant conclu-
sions can be highlighted. First, as can be seen in Fig. 1,
three sensitization clusters (sensitized to grass or olive alone
or the double sensitization to grass and olive) cover most of
the patients. In fact, in many areas, these frequencies cover
more than 90 % of patients with seasonal allergy. This was
not always evident as high exposure levels either to grass or
olive pollen cause minor allergen and pan-allergen sensiti-
zation, exemplified in the table by profilin prevalence data.
From a clinical perspective in many areas, the diagnostic
problem of pollen-allergic patients is limited to choosing
between grass, olive, or both [76]. There are specific tools
such as Phl 1, Phl p 5, Ole e 1, and Ole e 7, which together
with pan-allergen molecules will facilitate the diagnosis at
an affordable price.
Interestingly, in these studies, the other pollens, such as
Cypress or Salsola, in spite of sensitizing more than 50 % of
the patients, hardly ever monosensitize patients. The progres-
sion of disease in sensitization in a particular region can also
be analyzed. As an example in Madrid, the first three frequen-
cies in this order are grass alone, grass/olive, and grass/olive/
cypress. This finding suggests that grass pollen is the most
clinically relevant pollen in the area. The natural evolution of
sensitization in a particular region might help to choose clin-
ically dominant allergies or may help in the design of clinical
trials. For species that almost never monosensitize the popu-
lation, clinical trials might be designed to check the incremen-
tal benefit of adding an allergen to, for example, a grass-based
therapy.
In areas with low grass pollen counts, patients are still
sensitized to grasses but with a more complex profile. In these
regions, located along the Mediterranean border and dry inner
areas, patients are truly polysensitized. The first three frequen-
cies only covers a fraction of the allergic patients. Based on
our experience, we suggest that a cut-off value of 70 %
(patients covered by the first three sensitization frequencies)
could define the border between simple and complex pollen
areas. In complex areas, as grass pollen counts are relatively
low, profilin prevalence is also low, and thus, extract-based
SPT offers more value than in areas with a much lower
complexity, but higher pan-allergen prevalence. In areas with
close to 90% of patients monosensitized to grasses, but with a
prevalence of pan-allergens in the range of 30 %, extract-
based diagnosis is only causing diagnostic failure in 30 % of
patients.Ta
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In dry areas with extensive orchard tree cultivation (Teruel,
Huesca) especially peach trees, a significant fraction of pa-
tients with seasonal respiratory symptoms are monosensitized
to Pru p 3, the major allergen of peach and a severe food
allergen. This finding demonstrates a new entry gate to fruit
LTP-mediated allergy and supports the link between food and
respiratory allergies. In fact, the three most common allergies
affecting adults are related to PR10, LTPs, and profilin, all of
them connected to respiratory allergies
Knowing in advance the dynamics of sensitization will
help to define local diagnosis algorithms which will allow
an improved and effective diagnosis of allergic patients [2].
Fig. 1 Geographical distribution
of seasonal allergic patients that
are a grass monosensitized, b
olive monosensitized, and c co-
sensitized to grass and olive. Per-
centages of patient color codes are
shown on the right
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CRD is an increasingly appreciated tool that should com-
plement traditional diagnostic procedures to improve daily
clinical practice. Besides available methods, all of them com-
plex, time consuming, and relatively expensive, there is a need
for quick, inexpensive in vitro diagnostic tests adapted to the
different patient sensitization profiles. For example, a test for
Phl p 1,5, Ole 1, Ole e 7, profilin, and polcalcin would offer a
high diagnostic resolution capacity in most of the Spanish
territory. In a similar way, Phl p 1, 5 , Bet v 1, profilin, and
polcalcin would simplify pollen diagnosis in north and central
Europe. This last panel with the inclusion of Amb a 1 would
significantly improve pollen allergy diagnosis in North Amer-
ica. In this context, recent product diagnosis development
such as multiplexed assay recently commercialized [77] might
be of help.
Conclusions
Available data support that patients are usually sensitized to
not more than three or four primary sensitizers and that,
normally, it is possible to select one or two clinically relevant
ones for specific treatment. Correct diagnostic approaches to
identify clinically relevant sensitizers are possible with the
existing tools available today.
Sensitization analysis alone will never be enough as it is
necessary to carry this out in a clinically relevant context. For
this purpose, aerobiological data interpretation, knowledge of
patient sensitization patterns, and a deep understanding of the
connection of allergens with associated allergic diseases is
mandatory and constitutes the basis of allergy speciality.
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